Table 2.
Clinical features of hMPV-single-positive patients compared with RSV-single-positive patients and hMPV-RSV-double-negative patients.
| Characteristics | hMPV vs RSV | hMPV vs Non-RSV | ||||
|---|---|---|---|---|---|---|
| hMPV, N = 201 | RSV, N = 1,216 | p-valuea | hMPV, N = 201 | Non-RSV, N = 6,873 | p-valueb | |
| Age month (Median (IQR)) | 22.9 (12.7, 35.0) | 12.9 (6.3, 22.6) | < 0.001 | 22.9 (12.7, 35.0) | 17.9 (9.6, 30.1) | 0.003 |
| Age group (n (%)) | < 0.001 | < 0.001 | ||||
| 1–5 month | 11 (5.5%) | 17 (1.4%) | 11 (5.5%) | 578 (8.4%) | ||
| 6–11 month | 20 (10.0%) | 286 (23.5%) | 20 (10.0%) | 926 (13.5%) | ||
| 12–23 month | 56 (27.9%) | 383 (31.5%) | 56 (27.9%) | 2,252 (32.8%) | ||
| 24–35 month | 53 (26.4%) | 175 (14.4%) | 53 (26.4%) | 1,111 (16.2%) | ||
| 36–47 month | 19 (9.5%) | 57 (4.7%) | 19 (9.5%) | 485 (7.1%) | ||
| 48–59 month | 14 (7.0%) | 13 (1.1%) | 14 (7.0%) | 242 (3.5%) | ||
| ≧ 60 month | 28 (13.9%) | 285 (23.4%) | 28 (13.9%) | 1,279 (18.6%) | ||
| Sex (n (%)) | 0.005 | 0.004 | ||||
| Male | 97 (48.3%) | 716 (58.9%) | 97 (48.3%) | 4,023 (58.5%) | ||
| Female | 104 (51.7%) | 500 (41.1%) | 104 (51.7%) | 2,850 (41.5%) | ||
| Cough (n (%)) | 200 (99.5%) | 1,213 (99.8%) | 0.5 | 200 (99.5%) | 6,847 (99.6%) | 0.5 |
| Difficulty of breathing (n (%)) | 68 (33.8%) | 421 (34.6%) | 0.8 | 68 (33.8%) | 1,729 (25.2%) | 0.005 |
| Tachypnea (n (%)) | 150 (74.6%) | 955 (78.5%) | 0.2 | 150 (74.6%) | 5,653 (82.2%) | 0.006 |
| Chest indrawing (n (%)) | 11 (5.5%) | 100 (8.2%) | 0.2 | 11 (5.5%) | 299 (4.4%) | 0.4 |
| Stridor (n (%)) | 3 (1.5%) | 12 (1.0%) | 0.5 | 3 (1.5%) | 111 (1.6%) | > 0.9 |
| Wheeze (n (%)) | 105 (52.2%) | 687 (56.5%) | 0.3 | 105 (52.2%) | 3,017 (43.9%) | 0.019 |
| Crackle (n (%)) | 38 (18.9%) | 231 (19.0%) | > 0.9 | 38 (18.9%) | 785 (11.4%) | 0.001 |
| Clinical pneumonia (n (%)) | 0.6 | 0.010 | ||||
| No pneumonia | 148 (73.6%) | 915 (75.2%) | 148 (73.6%) | 5,559 (80.9%) | ||
| Pneumonia | 53 (26.4%) | 301 (24.8%) | 53 (26.4%) | 1,314 (19.1%) | ||
| Presence of danger sign (n (%)) | 5 (2.5%) | 37 (3.0%) | 0.7 | 5 (2.5%) | 162 (2.4%) | 0.8 |
| Body temperature (mean (SD)) | 38.0 (0.9) | 38.0 (0.8) | 0.5 | 38.0 (0.9) | 38.1 (0.9) | 0.8 |
| Duration of hospitalization (days, median (IQR)) | 5.0 (4.0, 6.0) | 5.0 (4.0, 6.0) | 0.8 | 5.0 (4.0, 6.0) | 4.0 (3.0, 6.0) | < 0.001 |
| Onset to hospitalization (days, Median (IQR)) | 2.0 (1.0, 3.0) | 3.0 (2.0, 4.0) | 0.016 | 2.0 (1.0, 3.0) | 2.0 (1.0, 4.0) | 0.7 |
| Unknown | 33 | 151 | 33 | 806 | ||
| Onset to discharge (days, median (IQR)) | 7.0 (6.0, 9.0) | 8.0 (6.0, 10.0) | 0.015 | 7.0 (6.0, 9.0) | 7.0 (5.0, 10.0) | 0.2 |
| Unknown | 33 | 151 | 33 | 806 | ||
IQR interquartile range, hMPV human metapneumovirus-single-positive group, RSV respiratory syncytial virus-single-positive group, Non-RSV human metapneumovirus–respiratory syncytial virus double-negative group.
aKruskal–Wallis rank sum test; Fisher’s Exact Test for Count Data with simulated p-value (based on 2000 replicates); Pearson’s Chi-squared test; Fisher’s exact test; Wilcoxon rank sum test.
bKruskal–Wallis rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; Wilcoxon rank sum test.